Table 1 Baseline patient characteristics

From: A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

Characteristic N = 18
On-study age—years  
Median 57
Range 25—81
Sex-no. (%)  
Female 10 (56)
Male 8 (44)
Ethnicity-no. (%)  
Non-hispanic white 7 (39)
Non-hispanic African-American 6 (33)
Other 5 (28)
Primary site (%)*  
Left colon/rectum 11 (61)
Right colon 6 (33)
Histologic grade  
Well differentiated 0 (0)
Moderately differentiated 14 (78)
Poorly differentiated 2 (11)
Unknown 2 (11)
Time from metastatic diagnosis-months  
Median 32
Range 4—172
Metastatic site (%)  
Liver only 4
Lymph nodes only 1
Bladder only 1
Multiple sites 12
Exposure to prior therapies (%)  
Fluoropyrimidine 18 (94)
Oxaliplatin 17 (94)
Irinotecan 17 (94)
Anti-VEGF 17 (94)
Anti-EGFR 8 (44)
KRAS mutation status  
Wild-type 7
Mutant 9
Unknown 2
Microsatellite Instability/Mismatch Repair Status  
MSI-H/dMMR 1
MSS/pMMR 12
Unknown 5
  1. *Unable to verify site of primary in 1 patient